BERGER FRANKLIN M — SEC insider filings
SEC reporting owner CIK 1273885. 46 insider filings on record with FilingPulse; latest filed 2026-10-13.
Transaction summary — filings shown
Covers all 46 filings on record, filed 2020-10-30 to 2026-10-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 19 legs across 12 filings — 632,063 shares, $8,085,542 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 3 filings — 674,112 shares, $1,967,211 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 82.
- Largest priced transaction: purchase of 120,000 shares @ $17.00 ($2,040,000) in Rain Oncology Inc., filed 2021-04-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Rain Oncology Inc. (RAIN) | Director | 8 | 6 legs · 293,667 sh · $3,410,826 | — | 11 |
| ESSA Pharma Inc. (EPIX) | Director | 9 | 4 legs · 156,730 sh · $2,091,935 | 7 legs · 272,840 sh · $729,052 | 15 |
| Atea Pharmaceuticals, Inc. (AVIR) | Director | 13 | 5 legs · 91,666 sh · $1,162,981 | 3 legs · 401,272 sh · $1,238,159 | 23 |
| Kezar Life Sciences, Inc. (KZR) | Director | 9 | 3 legs · 80,000 sh · $1,299,800 | — | 21 |
| Retension Pharmaceuticals, Inc. (RTSN) | Director | 3 | 1 leg · 10,000 sh · $120,000 | — | 3 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) | Director | 1 | — | — | 6 |
| Atreca, Inc. (BCEL) | Director | 3 | — | — | 3 |
Insider filings — BERGER FRANKLIN M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-13 | 4 | Retension Pharmaceuticals, Inc. (RTSN) | Conversion (C): 12,517 · Purchase (P): 10,000 @ $12 · Conversion (C): 12,517 (derivative) | EDGAR |
| 2026-10-08 | 3 | Retension Pharmaceuticals, Inc. (RTSN) | Holdings only — no transactions reported | EDGAR |
| 2026-10-08 | 4 | Retension Pharmaceuticals, Inc. (RTSN) | Grant/award (A): 5,636 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Kezar Life Sciences, Inc. (KZR) | Code (U): 89,069 · Disposition to issuer (D): 3,500 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 5,000 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | ESSA Pharma Inc. (EPIX) | Disposition to issuer (D): 784,404 | EDGAR |
| 2025-06-24 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4/A | Atea Pharmaceuticals, Inc. (AVIR) | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2025-01-17 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2024-12-12 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Sale (S): 359,606 @ $2.85 | EDGAR |
| 2024-06-21 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | ESSA Pharma Inc. (EPIX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-01-26 | 4 | Rain Oncology Inc. (RAIN) | Code (U): 1,005,207 · Disposition to issuer (D): 35,000 (derivative) · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2023-11-22 | 4 | ESSA Pharma Inc. (EPIX) | Purchase (P): 23,259 @ $5.73 | EDGAR |
| 2023-11-16 | 4 | ESSA Pharma Inc. (EPIX) | Purchase (P): 60,000 @ $5.35 · Purchase (P): 16,471 @ $5.99 | EDGAR |
| 2023-08-11 | 4 | Rain Oncology Inc. (RAIN) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-07-26 | 4 | Kezar Life Sciences, Inc. (KZR) | Disposition to issuer (D): 26,000 (derivative) · Grant/award (A): 26,000 (derivative) · Disposition to issuer (D): 26,000 (derivative) · Grant/award (A): 26,000 (derivative) | EDGAR |
| 2023-06-21 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 33,150 (derivative) @ $0 · Grant/award (A): 46,750 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | Atreca, Inc. (BCEL) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | ESSA Pharma Inc. (EPIX) | Sale (S): 25,000 @ $3 · Sale (S): 32,000 @ $2.90 · Sale (S): 50,000 @ $2.86 · Sale (S): 50,000 @ $2.67 · Sale (S): 43,617 @ $2.53 · Sale (S): 37,889 @ $2.41 · +1 more | EDGAR |
| 2022-11-23 | 4 | Rain Therapeutics Inc. (RAIN) | Purchase (P): 45,000 @ $7.80 · Purchase (P): 77,000 @ $8.27 | EDGAR |
| 2022-11-15 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Sale (S): 25,500 @ $5.15 · Sale (S): 16,166 @ $5.16 | EDGAR |
| 2022-11-14 | 4 | Rain Therapeutics Inc. (RAIN) | Purchase (P): 42,881 @ $5.83 | EDGAR |
| 2022-11-01 | 4 | ESSA Pharma Inc. (EPIX) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2022-08-19 | 4 | Rain Therapeutics Inc. (RAIN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 61,264 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Atreca, Inc. (BCEL) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Kezar Life Sciences, Inc. (KZR) | Purchase (P): 15,000 @ $15.96 · Purchase (P): 45,000 @ $17 · Purchase (P): 20,000 @ $14.77 | EDGAR |
| 2021-09-23 | 4 | Rain Therapeutics Inc. (RAIN) | Purchase (P): 3,786 @ $14.30 | EDGAR |
| 2021-09-23 | 4 | Kezar Life Sciences, Inc. (KZR) | Option exercise (M): 8,896 @ $5.91 · Option exercise (M): 8,896 @ $7.63 · Option exercise (M): 8,896 @ $5.60 · Option exercise (M): 8,896 (derivative) @ $0 · Option exercise (M): 8,896 (derivative) @ $0 · Option exercise (M): 8,896 (derivative) @ $0 | EDGAR |
| 2021-06-30 | 4 | Kezar Life Sciences, Inc. (KZR) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 34,025 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Atreca, Inc. (BCEL) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Rain Therapeutics Inc. (RAIN) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2021-04-27 | 4 | Rain Therapeutics Inc. (RAIN) | Purchase (P): 120,000 @ $17 · Purchase (P): 5,000 @ $15.78 · Conversion (C): 175,939 · Conversion (C): 535,601 · Conversion (C): 189,998 (derivative) @ $0 · Conversion (C): 578,397 (derivative) @ $0 | EDGAR |
| 2021-04-19 | 4 | FIVE PRIME THERAPEUTICS, INC. (FPRX) | Disposition to issuer (D): 5,000 @ $38 · Disposition to issuer (D): 12,500 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) | EDGAR |
| 2021-03-04 | 4 | ESSA Pharma Inc. (EPIX) | Purchase (P): 57,000 @ $27 | EDGAR |
| 2021-01-26 | 4/A | ESSA Pharma Inc. (EPIX) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2021-01-11 | 4 | ESSA Pharma Inc. (EPIX) | Option exercise (M): 1,716 @ $4 · Option exercise (M): 6,534 @ $4 · Option exercise (M): 2,184 @ $3.81 · Option exercise (M): 25,000 @ $3.23 · Option exercise (M): 6,773 @ $4.67 · Option exercise (M): 1,716 (derivative) @ $0 · +5 more | EDGAR |
| 2020-11-03 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Conversion (C): 759,606 · Purchase (P): 41,666 @ $24 · Conversion (C): 400,000 (derivative) · Conversion (C): 132,014 (derivative) · Conversion (C): 131,578 (derivative) · Conversion (C): 60,540 (derivative) · +1 more | EDGAR |
| 2020-10-30 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1273885 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs